Drugs in the Pipeline

Tavapadon is an oral, once-daily, selective dopamine D1/D5 receptor partial agonist designed to improve motor control while avoiding D2/D3 overstimulation.

The double-blind, phase 3 study included 2 groups of patients, those who were not on positive airway pressure therapy and those who were.

A regulatory decision is expected on February 14, 2025.

LX2006 (AAVrh.10hFXN) is an adeno-associated virus gene therapy candidate designed to deliver a functional frataxin gene to cardiac cells to improve mitochondrial function.

The phase 3 study evaluated the efficacy and safety of lumateperone as an adjunctive treatment to antidepressants in 485 patients with MDD.

NM5072 is a potential first-in-class monoclonal antibody that selectively blocks properdin, a protein of the complement alternative pathway.

The table below is a review of notable updates that occurred in March 2024 for investigational products in development.

SuVax is a subunit protein vaccine of recombinantly expressed Sudan ebolavirus glycoprotein.

The Food and Drug Administration (FDA) has granted Fast Track designation to enibarcimab for the treatment of septic shock. Enibarcimab (formerly adrecizumab) is a first-in-class non-neutralizing monoclonal antibody that binds to adrenomedullin (ADM), a vasoprotective hormone. It is believed that modulating the ADM pathway may improve outcomes in patients with septic shock. The Fast Track…

Tamibarotene is an oral selective retinoic acid receptor alpha (RARα) agonist.